{"id":61172,"date":"2026-03-24T22:46:33","date_gmt":"2026-03-24T14:46:33","guid":{"rendered":"https:\/\/flcube.com\/?p=61172"},"modified":"2026-03-24T22:46:34","modified_gmt":"2026-03-24T14:46:34","slug":"fosun-pharma-reports-2025-results-innovative-drug-revenue-surges-30-to-rmb-9-9-billion-overseas-sales-hit-rmb-13-billion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61172","title":{"rendered":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion"},"content":{"rendered":"\n

Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (SHA: 600196<\/a>, HKG: 2196<\/a>) announced 2025 annual operating results<\/strong>, demonstrating accelerated transformation<\/strong> toward innovation and globalization. Total operating revenue reached RMB 41.662 billion<\/strong> (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion<\/strong> \u2013 now 33.16% of pharmaceutical sales<\/strong>. Overseas revenue grew 14.87% to RMB 12.977 billion<\/strong> (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion<\/strong>.<\/p>\n\n\n\n

Financial Highlights<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change<\/th>Strategic Significance<\/th><\/tr><\/thead>
Total Operating Revenue<\/strong><\/td>RMB 41.662 billion<\/td>+1.45%<\/td>Stable base amid portfolio optimization<\/td><\/tr>
Innovative Drug Revenue<\/strong><\/td>RMB 9.893 billion<\/td>+29.59%<\/strong><\/td>Core growth engine<\/strong> \u2013 33.16% of pharma sales<\/td><\/tr>
Overseas Revenue<\/strong><\/td>RMB 12.977 billion<\/td>+14.87%<\/strong><\/td>31.15% of total<\/strong> (+3.64pp) \u2013 globalization accelerating<\/td><\/tr>
Net Profit (Parent)<\/strong><\/td>RMB 3.371 billion<\/td>+21.69%<\/strong><\/td>Margin expansion from high-value innovation<\/td><\/tr>
Recurring Net Profit<\/strong><\/td>RMB 2.34 billion<\/td>+1.12%<\/td>Sustainable earnings quality<\/td><\/tr>
Operating Cash Flow<\/strong><\/td>RMB 5.213 billion<\/td>+16.45%<\/strong><\/td>Strong cash generation supports R&D intensity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

R&D Investment & Pipeline Productivity<\/h2>\n\n\n\n
R&D Metric<\/th>2025 Result<\/th>YoY Change<\/th>Innovation Focus<\/th><\/tr><\/thead>
Total R&D Investment<\/strong><\/td>RMB 5.913 billion<\/td>+6.46%<\/td>Sustained high-intensity investment<\/td><\/tr>
Innovative Pharma R&D<\/strong><\/td>RMB 4.303 billion<\/td>+15.98%<\/strong><\/td>80.26%<\/strong> of pharma R&D \u2013 prioritization clear<\/td><\/tr>
New Approvals (Indications)<\/strong><\/td>16 indications of 7 drugs<\/strong><\/td>\u2014<\/td>China + overseas regulatory success<\/td><\/tr>
NDAs Accepted<\/strong><\/td>6 candidates<\/strong><\/td>\u2014<\/td>Near-term commercialization pipeline<\/td><\/tr>
Clinical Trial Approvals<\/strong><\/td>~40 trials<\/strong> (China + global)<\/td>\u2014<\/td>Robust late-stage engine<\/td><\/tr>
NRDL Inclusions (2025)<\/strong><\/td>5 innovative drugs<\/strong><\/td>\u2014<\/td>Reimbursement access unlocking volume<\/td><\/tr>
Commercial Insurance Listing<\/strong><\/td>Yikaida (CAR-T)<\/strong> in 1st Catalog<\/td>\u2014<\/td>Alternative payment pathway for cell therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapeutic Area Progress<\/h2>\n\n\n\n
Segment<\/th>2025 Milestones<\/th>Strategic Impact<\/th><\/tr><\/thead>
Oncology<\/strong><\/td>Fumaining\u00ae (luvometinib) 2 approvals \u2013 rare tumor gap filled; Futuoning\u00ae (CDK4\/6) launched for breast cancer; Serplulimab EU approval for ES-SCLC \u2013 first China PD-1 in EU<\/strong>; HLX43\/HLX22 ADCs enter key phases; Brexucabtagene Autoleucel NDA accepted<\/td>Global oncology franchise<\/strong> established with biosimilars, PD-1, ADCs, CAR-T<\/td><\/tr>
Immune\/Inflammation<\/strong><\/td>Wantile (Tenapanor) approved \u2013 CKD dialysis indication; FXS7553 clinical progress<\/td>Renal-metabolic<\/strong> expansion beyond oncology<\/td><\/tr>
Neurodegenerative<\/strong><\/td>Opicapone (Parkinson’s) Boao launch; MRgFUS upgrade; Sodium Oligomannate post-marketing trials; AR1001 Phase III global<\/td>Long-term CNS pipeline<\/strong> for aging populations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platforms & Global Licensing<\/h2>\n\n\n\n
Platform<\/th>2025 Progress<\/th>Deal Value<\/th><\/tr><\/thead>
Radiopharmaceuticals<\/strong><\/td>SRT-007 Phase I initiated \u2013 “imaging + therapy” pathway<\/td>\u2014<\/td><\/tr>
Cell Therapy<\/strong><\/td>FKC289 (dual-target CAR-T) NMPA IND accepted<\/td>\u2014<\/td><\/tr>
GLP-1 (YP05002)<\/strong><\/td>Global out-license<\/strong> \u2013 largest deal of 2025<\/td>$150M upfront + $2.085B total<\/strong><\/td><\/tr>
Total Out-Licensing<\/strong><\/td>$260M+ upfront<\/strong> across all deals<\/td>$3.8B+ potential milestones<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Global Partnerships:<\/strong> Teva joint development (FXB0871); Aditum Bio fund collaboration; Akynzeo, Pu Rui Ni, Daxxify China in-licensing approvals<\/p>\n\n\n\n

Globalization: “System-Centric” Upgrade<\/h2>\n\n\n\n
Capability<\/th>2025 Achievement<\/th>Geographic Reach<\/th><\/tr><\/thead>
Serplulimab<\/strong><\/td>Approved 40+ countries<\/strong>; U.S. bridging study enrolled; BLA submission 2026<\/strong><\/td>China, EU, emerging markets, U.S. (pending)<\/td><\/tr>
Biosimilars<\/strong><\/td>Denosumab FDA + EU approvals<\/strong> \u2013 biologics platform certified to international standards<\/td>Global supply to Europe, LatAm, SE Asia, India<\/td><\/tr>
GMP Certifications<\/strong><\/td>17 workshops\/lines<\/strong> passed U.S., EU, WHO GMP<\/td>Quality foundation for global supply<\/td><\/tr>
Manufacturing Scale<\/strong><\/td>Biologics regular global supply<\/strong>; Gland Pharma injections EU\/U.S.\/Japan\/Australia certified<\/strong><\/td>Supply chain resilience across 6+ regions<\/td><\/tr>
Commercial Presence<\/strong><\/td>6,000+ personnel worldwide<\/strong>; Africa 40+ countries<\/strong>; Sisram 110+ countries<\/strong>; Breas 50+ countries<\/strong><\/td>“Independent operation + licensing” dual model<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding 2026 BLA submissions, NRDL negotiations, and global expansion execution. Actual results may differ due to regulatory review timelines, competitive dynamics in oncology and metabolic diseases, and geopolitical factors affecting China-origin pharmaceutical exports.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating…<\/p>\n","protected":false},"author":1,"featured_media":61173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,159,893,892],"class_list":["post-61172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"\nFosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61172\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:46:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T14:46:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion\",\"datePublished\":\"2026-03-24T14:46:33+00:00\",\"dateModified\":\"2026-03-24T14:46:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172\"},\"wordCount\":516,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2407-1.webp\",\"keywords\":[\"Finanical Reports\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61172#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61172\",\"name\":\"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2407-1.webp\",\"datePublished\":\"2026-03-24T14:46:33+00:00\",\"dateModified\":\"2026-03-24T14:46:34+00:00\",\"description\":\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2407-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2407-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion - Insight, China's Pharmaceutical Industry","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61172","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion","og_description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.","og_url":"https:\/\/flcube.com\/?p=61172","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-24T14:46:33+00:00","article_modified_time":"2026-03-24T14:46:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61172#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61172"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion","datePublished":"2026-03-24T14:46:33+00:00","dateModified":"2026-03-24T14:46:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61172"},"wordCount":516,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","keywords":["Finanical Reports","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61172#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61172","url":"https:\/\/flcube.com\/?p=61172","name":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61172#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","datePublished":"2026-03-24T14:46:33+00:00","dateModified":"2026-03-24T14:46:34+00:00","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion \u2013 now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61172#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","width":1080,"height":608,"caption":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Reports 2025 Results \u2013 Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2407-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61172"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61172\/revisions"}],"predecessor-version":[{"id":61174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61172\/revisions\/61174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}